Women's perspectives on impact on the post menopause of use of the 52 mg levonorgestrel intrauterine device during the menopausal transition

Eur J Contracept Reprod Health Care. 2023 Aug;28(4):207-209. doi: 10.1080/13625187.2023.2202292. Epub 2023 May 30.

Abstract

Objectives: To assess perimenopausal users of 52 mg levonorgestrel intrauterine devices (LNG-IUD) regarding the IUD impact after menopause.

Material and methods: a cross-sectional study with users aged 40 and 49 years old, without cognitive impairment that answered a questionnaire regarding worries and benefits after the menopause due to LNG-IUD use.

Results: Almost half of 221 users (52.9%) have concerns that LNG-IUD use could influence aspects after menopause, 111 (50.3%) that the post-menopause symptoms get worse and 92 (41.6%) that interfere with recognition of menopausal symptoms.

Conclusion: Half of perimenopausal LNG-IUD users expressed concerns about how device use could affect post-menopause symptoms.

Keywords: 52 mg levonorgestrel intrauterine device; LNG-IUD; menopausal transition.

Plain language summary

The 52 mg hormonal-IUD who were at menopausal transition reported worries that the use of the IUD can affect menopausal symptoms. It is important that health professionals can routinely guide these women.

MeSH terms

  • Adult
  • Contraceptive Agents, Female*
  • Cross-Sectional Studies
  • Female
  • Humans
  • Intrauterine Devices*
  • Intrauterine Devices, Copper*
  • Intrauterine Devices, Medicated* / adverse effects
  • Levonorgestrel
  • Menopause
  • Middle Aged
  • Postmenopause

Substances

  • Levonorgestrel
  • Contraceptive Agents, Female